REduced Frequency ImmuNE Checkpoint Inhibition in Cancers
Status:
Not yet recruiting
Trial end date:
2025-04-01
Target enrollment:
Participant gender:
Summary
The REFINE trial aims to asses whether giving an immunotherapy drug less-often to patients
with advanced cancer, results in fewer side effects whilst continuing to be an effective
treatment. The question will be assessed in different tumour types by means of different
cohorts within an overarching trial protocol.
Phase:
Phase 2
Details
Lead Sponsor:
University College, London
Collaborators:
Jon Moulton Charity Trust JP Moulton Charitable Trust